Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

被引：61

作者：

Hjorth-Hansen, H. ^{[1
,2
]}

Stentoft, J. ^{[3
]}

Richter, J. ^{[4
]}

Koskenvesa, P. ^{[5
,6
]}

Hoeglund, M. ^{[7
]}

Dreimane, A. ^{[8
]}

Porkka, K. ^{[5
,6
]}

Gedde-Dahl, T. ^{[9
]}

Gjertsen, B. T. ^{[10
,11
]}

Gruber, F. X. ^{[12
]}

Stenke, L. ^{[13
,14
]}

Eriksson, K. M. ^{[15
]}

Markevarn, B. ^{[16
]}

Lubking, A. ^{[5
,6
]}

Vestergaard, H. ^{[17
]}

Udby, L. ^{[18
]}

Bjerrum, O. W. ^{[19
]}

Persson, I. ^{[20
]}

Mustjoki, S. ^{[5
,6
,21
]}

Olsson-Stromberg, U. ^{[7
]}

机构：

[1] St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway

[2] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway

[3] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark

[4] Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden

[5] Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland

[6] Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden

[7] Univ Uppsala Hosp, Dept Hematol, Uppsala, Sweden

[8] Linkoping Univ, Dept Med & Hlth Sci, Dept Hematol, Cty Council Ostergotland, Linkoping, Sweden

[9] Oslo Univ Hosp, Rikshosp, Dept Hematol, Oslo, Norway

[10] Haukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway

[11] Univ Bergen, Dept Clin Sci, Bergen, Norway

[12] Univ Hosp North Norway, Dept Hematol, Tromso, Norway

[13] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden

[14] Karolinska Inst, Stockholm, Sweden

[15] Sunderbysjukhuset, Dept Internal Med, Lulea, Sweden

[16] Umea Univ Hosp, Dept Hematol, Umea, Sweden

[17] Odense Univ Hosp, Dept Hematol, Odense, Denmark

[18] Roskilde Hosp, Dept Hematol, Roskilde, Denmark

[19] Univ Copenhagen Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[20] Uppsala Univ, Dept Stat, Uppsala, Sweden

[21] Univ Helsinki, Dept Clin Chem, Helsinki, Finland

来源：

LEUKEMIA | 2016年 / 30卷 / 09期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; DEEP MOLECULAR RESPONSE; FOLLOW-UP; PEGINTERFERON ALPHA-2A; OCCLUSIVE DISEASE; IMATINIB MESYLATE; RANDOMIZED-TRIAL; OPEN-LABEL; 400; MG;

D O I：

10.1038/leu.2016.121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.

引用

页码：1853 / 1860

页数：8

共 50 条

[1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts [J].

Abboud, Camille ;

Berman, Ellin ;

Cohen, Adam ;

Cortes, Jorge ;

DeAngelo, Daniel ;

Deininger, Michael ;

Devine, Steven ;

Druker, Brian ;

Fathi, Amir ;

Jabbour, Elias ;

Jagasia, Madan ;

Kantarjian, Hagop ;

Khoury, Jean ;

Laneuville, Pierre ;

Larson, Richard ;

Lipton, Jeffrey ;

Moore, Joseph O. ;

Mughal, Tariq ;

O'Brien, Susan ;

Pinilla-Ibarz, Javier ;

Quintas-Cardama, Alfonso ;

Radich, Jerald ;

Reddy, Vishnu ;

Schiffer, Charles ;

Shah, Neil ;

Shami, Paul ;

Silver, Richard T. ;

Snyder, David ;

Stone, Richard ;

Talpaz, Moshe ;

Tefferi, Ayalew ;

Van Etten, Richard A. ;

Wetzler, Meir ;

Abruzzese, Elisabetta ;

Apperley, Jane ;

Breccia, Massimo ;

Byrne, Jenny ;

Cervantes, Francisco ;

Chelysheva, Ekaterina ;

Clark, R. E. ;

de Lavallade, Hugues ;

Dyagil, Iryna ;

Gambacorti-Passerini, Carlo ;

Goldman, John ;

Haznedaroglu, Ibrahim ;

Hjorth-Hansen, Henrik ;

Holyoake, Tessa ;

Huntly, Brian ;

le Coutre, Philipp ;

Lomaia, Elza .

BLOOD, 2013, 121 (22) :4439-4442

[2] Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia [J].

Baccarani, M ;

Martinelli, G ;

Rosti, G ;

Trabacchi, E ;

Testoni, N ;

Bassi, S ;

Amabile, M ;

Soverini, S ;

Castagnetti, F ;

Cilloni, D ;

Izzo, B ;

de Vivo, A ;

Messa, E ;

Bonifazi, F ;

Poerio, A ;

Luatti, S ;

Giugliano, E ;

Alberti, D ;

Fincato, G ;

Russo, D ;

Pane, F ;

Saglio, G .

BLOOD, 2004, 104 (13) :4245-4251

[3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[4] Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor [J].

Bhattacharya, Sabyasachi ;

Zheng, Hui ;

Tzimas, Christos ;

Carroll, Martin ;

Baker, Darren P. ;

Fuchs, Serge Y. .

BLOOD, 2011, 118 (15) :4179-4187

[5] Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia [J].

Burchert, A ;

Wölfl, S ;

Schmidt, M ;

Brendel, C ;

Denecke, B ;

Cai, D ;

Odyvanova, L ;

Lahaye, T ;

Müller, MC ;

Berg, T ;

Gschaidmeier, H ;

Wittig, B ;

Hehlmann, R ;

Hochhaus, A ;

Neubauer, A .

BLOOD, 2003, 101 (01) :259-264

[6] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[7] Immune Modulation of Minimal Residual Disease in Early Chronic Phase Chronic Myelogenous Leukemia A Randomized Trial of Frontline High-Dose Imatinib Mesylate With or Without Pegylated Interferon Alpha-2b and Granulocyte-Macrophage Colony-Stimulating Factor [J].

Cortes, Jorge ;

Quintas-Cardama, Alfonso ;

Jones, Dan ;

Ravandi, Farhad ;

Garcia-Manero, Guillermo ;

Verstovsek, Srdan ;

Koller, Charles ;

Hiteshew, Jody ;

Shan, Jenny ;

O'Brien, Susan ;

Kantarjian, Hagop .

CANCER, 2011, 117 (03) :572-580

[8] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Dyagil, Irina ;

Griskevicius, Laimonas ;

Malhotra, Hemant ;

Powell, Christine ;

Gogat, Karin ;

Countouriotis, Athena M. ;

Gambacorti-Passerini, Carlo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492

[9] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study [J].

Cortes, Jorge E. ;

Baccarani, Michele ;

Guilhot, Francois ;

Druker, Brian J. ;

Branford, Susan ;

Kim, Dong-Wook ;

Pane, Fabrizio ;

Pasquini, Ricardo ;

Goldberg, Stuart L. ;

Kalaycio, Matt ;

Moiraghi, Beatriz ;

Rowe, Jacob M. ;

Tothova, Elena ;

De Souza, Carmino ;

Rudoltz, Marc ;

Yu, Richard ;

Krahnke, Tillmann ;

Kantarjian, Hagop M. ;

Radich, Jerald P. ;

Hughes, Timothy P. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) :424-430

[10] Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia [J].

Cross, N. C. P. ;

White, H. E. ;

Colomer, D. ;

Ehrencrona, H. ;

Foroni, L. ;

Gottardi, E. ;

Lange, T. ;

Lion, T. ;

Polakova, K. Machova ;

Dulucq, S. ;

Martinelli, G. ;

Leibundgut, E. Oppliger ;

Pallisgaard, N. ;

Barbany, G. ;

Sacha, T. ;

Talmaci, R. ;

Izzo, B. ;

Saglio, G. ;

Pane, F. ;

Mueller, M. C. ;

Hochhaus, A. .

LEUKEMIA, 2015, 29 (05) :999-1003

← 1 2 3 4 5 →